JP5975884B2 - ソフトゲルカプセル化のためのナプロキセンの医薬処方およびその組合せ - Google Patents

ソフトゲルカプセル化のためのナプロキセンの医薬処方およびその組合せ Download PDF

Info

Publication number
JP5975884B2
JP5975884B2 JP2012549215A JP2012549215A JP5975884B2 JP 5975884 B2 JP5975884 B2 JP 5975884B2 JP 2012549215 A JP2012549215 A JP 2012549215A JP 2012549215 A JP2012549215 A JP 2012549215A JP 5975884 B2 JP5975884 B2 JP 5975884B2
Authority
JP
Japan
Prior art keywords
acid
ranges
naproxen
amount
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012549215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013517304A (ja
JP2013517304A5 (cg-RX-API-DMAC10.html
Inventor
ジョン・ロペス
ピーター・ドレイパー
サンカルプ・ヴァシシュサ
ナンシー・クラッセン
クリスティーナ・アームストロング
Original Assignee
アキュキャップス・インダストリーズ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アキュキャップス・インダストリーズ・リミテッド filed Critical アキュキャップス・インダストリーズ・リミテッド
Publication of JP2013517304A publication Critical patent/JP2013517304A/ja
Publication of JP2013517304A5 publication Critical patent/JP2013517304A5/ja
Application granted granted Critical
Publication of JP5975884B2 publication Critical patent/JP5975884B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012549215A 2010-01-19 2011-01-19 ソフトゲルカプセル化のためのナプロキセンの医薬処方およびその組合せ Active JP5975884B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2,690,488 2010-01-19
CA2690488A CA2690488C (en) 2010-01-19 2010-01-19 Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
PCT/CA2011/000059 WO2011088553A1 (en) 2010-01-19 2011-01-19 Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016007253A Division JP2016094462A (ja) 2010-01-19 2016-01-18 ソフトゲルカプセル化のためのナプロキセンの医薬処方およびその組合せ

Publications (3)

Publication Number Publication Date
JP2013517304A JP2013517304A (ja) 2013-05-16
JP2013517304A5 JP2013517304A5 (cg-RX-API-DMAC10.html) 2014-03-06
JP5975884B2 true JP5975884B2 (ja) 2016-08-23

Family

ID=44303618

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012549215A Active JP5975884B2 (ja) 2010-01-19 2011-01-19 ソフトゲルカプセル化のためのナプロキセンの医薬処方およびその組合せ
JP2016007253A Pending JP2016094462A (ja) 2010-01-19 2016-01-18 ソフトゲルカプセル化のためのナプロキセンの医薬処方およびその組合せ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016007253A Pending JP2016094462A (ja) 2010-01-19 2016-01-18 ソフトゲルカプセル化のためのナプロキセンの医薬処方およびその組合せ

Country Status (13)

Country Link
US (5) US9480667B2 (cg-RX-API-DMAC10.html)
EP (2) EP3909567B1 (cg-RX-API-DMAC10.html)
JP (2) JP5975884B2 (cg-RX-API-DMAC10.html)
AU (1) AU2011207061B2 (cg-RX-API-DMAC10.html)
CA (1) CA2690488C (cg-RX-API-DMAC10.html)
DK (1) DK2525789T3 (cg-RX-API-DMAC10.html)
ES (1) ES2880813T3 (cg-RX-API-DMAC10.html)
HU (1) HUE055771T2 (cg-RX-API-DMAC10.html)
MX (1) MX358636B (cg-RX-API-DMAC10.html)
PL (1) PL2525789T3 (cg-RX-API-DMAC10.html)
PT (1) PT2525789T (cg-RX-API-DMAC10.html)
SI (1) SI2525789T1 (cg-RX-API-DMAC10.html)
WO (1) WO2011088553A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MX375328B (es) 2014-06-04 2025-03-06 Ds Biopharma Ltd Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas
CN104083339A (zh) * 2014-08-04 2014-10-08 人福普克药业（武汉）有限公司 萘普生钠软胶囊及其制备方法
US10368284B2 (en) * 2014-11-12 2019-07-30 T-Mobile Usa, Inc. Quality of experience-based handover management
US10047033B2 (en) 2015-05-13 2018-08-14 Ds Biopharma Limited Compositions comprising oxo-derivatives of fatty acids and methods of making and using same
CN112245420A (zh) 2015-07-21 2021-01-22 艾菲穆恩有限公司 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物
AU2016370626B2 (en) 2015-12-18 2020-08-20 Afimmune Limited Compositions comprising 15-HEPE and methods of using the same
CR20200552A (es) 2018-05-16 2021-05-13 Bayer Healthcare Llc Fórmula de suspención de alta concentración para medicamentos en cápsula de gel blanda paae resfriado y gripe
CN109692127A (zh) * 2019-03-15 2019-04-30 王征 一种密封小胶囊的制备方法
AU2020263295B2 (en) * 2019-04-26 2025-01-23 R.P. Scherer Technologies, Llc Mini softgel naproxen composition
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US20220233452A1 (en) * 2021-01-25 2022-07-28 R.P. Scherer Technologies, Llc Mini softgel naproxen composition

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA821577B (en) 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US5071643A (en) * 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
US5073371A (en) 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
WO1995007103A1 (en) 1993-09-07 1995-03-16 The Procter & Gamble Company Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive
US5484606A (en) * 1994-01-24 1996-01-16 The Procter & Gamble Company Process for reducing the precipitation of difficulty soluble pharmaceutical actives
AU706890B2 (en) * 1994-01-24 1999-07-01 Procter & Gamble Company, The Process for solubilizing difficultly soluble pharmaceutical actives
US5641512A (en) 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
US6287594B1 (en) * 1998-01-20 2001-09-11 Edward S. Wilson Oral liquid compositions
US6383515B2 (en) * 1999-05-28 2002-05-07 Sawyer Maryjean Solvent system for enhancing solubility
US6387400B1 (en) 2000-08-29 2002-05-14 R.P. Scherer Technologies, Inc. Process for preparing pharmaceutical compositions for use with soft gelatin formulations
US20090318558A1 (en) * 2003-02-12 2009-12-24 Jae-Hwan Kim Solvent system of hardly soluble drug with improved dissolution rate
WO2004071490A1 (en) * 2003-02-12 2004-08-26 R & P Korea Co., Ltd. Solvent system of hardly soluble drug with improved elution rate
US20070053868A1 (en) * 2005-03-08 2007-03-08 Banner Pharmacaps, Inc. Solvent system for enhancing the solubility of pharmaceutical agents
US7582679B2 (en) 2006-02-03 2009-09-01 Pharmaceutics International Incorporated Compositions containing solid ibuprofen concentrates and methods of making solid ibuprofen concentrates
US20080014274A1 (en) * 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
US20110052679A1 (en) * 2009-08-25 2011-03-03 Pharmaceutics International, Inc. Solid naproxen concentrates and related dosage forms

Also Published As

Publication number Publication date
US12605348B2 (en) 2026-04-21
US20260216111A1 (en) 2026-07-30
CA2690488A1 (en) 2011-07-19
WO2011088553A1 (en) 2011-07-28
JP2016094462A (ja) 2016-05-26
AU2011207061A1 (en) 2012-07-26
PL2525789T3 (pl) 2022-01-03
EP2525789A1 (en) 2012-11-28
MX2012008300A (es) 2012-11-23
US10463637B2 (en) 2019-11-05
DK2525789T3 (da) 2021-07-19
EP3909567C0 (en) 2026-04-29
JP2013517304A (ja) 2013-05-16
SI2525789T1 (sl) 2021-12-31
EP3909567B1 (en) 2026-04-29
CA2690488C (en) 2013-06-11
EP3909567A1 (en) 2021-11-17
EP2525789A4 (en) 2014-04-30
US11896566B2 (en) 2024-02-13
MX358636B (es) 2018-08-29
US20240139132A1 (en) 2024-05-02
AU2011207061B2 (en) 2015-05-28
EP2525789B1 (en) 2021-06-02
US9480667B2 (en) 2016-11-01
US20170020832A1 (en) 2017-01-26
PT2525789T (pt) 2021-07-19
US20130011470A1 (en) 2013-01-10
US20200046662A1 (en) 2020-02-13
HUE055771T2 (hu) 2021-12-28
ES2880813T3 (es) 2021-11-25

Similar Documents

Publication Publication Date Title
US12605348B2 (en) Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
US5505961A (en) Gelatin capsules containing a highly concentrated acetaminophen solution
US20030232097A1 (en) Oily wax matrix suspension formulation comprising ibuprofen free acid and potassium salt of ibuprofen
WO2009066146A2 (en) Stable solutions of sparingly soluble actives
WO1995019792A1 (en) Process for reducing the precipitation of difficultly soluble pharmaceutical actives
JPH09508128A (ja) 難溶性医薬活性剤の溶解方法
WO2005046727A2 (en) Ibuprofen-containing soft gelatin capsules
JP3382076B2 (ja) イブプロフェンを溶解してなるかぜ薬軟カプセル及びその製造方法
JP4394447B2 (ja) アセトアミノフェン組成物
US6383515B2 (en) Solvent system for enhancing solubility
WO2016084099A1 (en) Soft gelatin capsule composition of anti-tussive agents
CN103687592A (zh) 包含非索非那定的药物组合物
JP2006089415A (ja) カフェイン含有カプセル製剤
CA3207235A1 (en) Concentrated liquid gel formulations containing naproxen salts

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150622

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160118

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160523

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160620

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160719

R150 Certificate of patent or registration of utility model

Ref document number: 5975884

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250